Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential

Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiricozzi, Andrea, De Simone, Clara, Fossati, Barbara, Peris, Ketty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538010/
https://www.ncbi.nlm.nih.gov/pubmed/31214486
http://dx.doi.org/10.2147/PTT.S179283
_version_ 1783422112143245312
author Chiricozzi, Andrea
De Simone, Clara
Fossati, Barbara
Peris, Ketty
author_facet Chiricozzi, Andrea
De Simone, Clara
Fossati, Barbara
Peris, Ketty
author_sort Chiricozzi, Andrea
collection PubMed
description Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.
format Online
Article
Text
id pubmed-6538010
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65380102019-06-18 Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential Chiricozzi, Andrea De Simone, Clara Fossati, Barbara Peris, Ketty Psoriasis (Auckl) Mini-Review Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents. Dove 2019-05-24 /pmc/articles/PMC6538010/ /pubmed/31214486 http://dx.doi.org/10.2147/PTT.S179283 Text en © 2019 Chiricozzi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Mini-Review
Chiricozzi, Andrea
De Simone, Clara
Fossati, Barbara
Peris, Ketty
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_full Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_fullStr Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_full_unstemmed Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_short Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
title_sort emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538010/
https://www.ncbi.nlm.nih.gov/pubmed/31214486
http://dx.doi.org/10.2147/PTT.S179283
work_keys_str_mv AT chiricozziandrea emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential
AT desimoneclara emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential
AT fossatibarbara emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential
AT perisketty emergingtreatmentoptionsforthetreatmentofmoderatetosevereplaquepsoriasisandpsoriaticarthritisevaluatingbimekizumabanditstherapeuticpotential

Ejemplares similares